BioSense

Paradigm. Aging is a total chronic disease (TCD) affecting all multicellular animals and humans from the moment of conception. All other chronic diseases—cardiovascular, oncological, neurodegenerative, psychiatric, sarcopenia—are exacerbations or complications of this underlying disease.

Problem. Current medicine treats exacerbations without measuring the activity of the primary disease. Wearable devices collect signals without a theoretical framework.

Solution—BioSense. We present BioSense, a wearable platform that: (1) measures aging activity via the χ_Ze index (Ze cheating index)—a theoretically derived index from Ze Vectors Theory—computed from EEG, HRV, respiration, and sleep patterns; (2) provides preliminary estimates of 30-day exacerbation risk (bootstrap-corrected AUC 0.76–0.88, 95% CI: 0.71–0.93, prospective pilot cohort N=150, 9 months; external validation on N≥500 is required and planned); (3) follows strict evidence-based standards (preregistration OSF, α=0.00025, publication of all results); (4) optionally integrates polygenic risk scores (PRS), adding 6–11% AUC over the base model; (5) is embedded within the FCLC (Federated Clinical Learning Cooperative) data infrastructure with five-layer differential privacy (ε=2.0, k-anonymity k≥7) and anti-discrimination safeguards.